Clinical Trial Update: Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC [Phase 3]

View source ↗

Summary

A Phase 3 trial examining Lurbinectedin alone or with Irinotecan versus Topotecan in relapsed small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan (Irinotecan)
• Lurbinectedin (lurbinectedin)
• Topotecan (topotecan)

Snippet

Sponsor: Luye Pharma Group Ltd. | Conditions: Relapsed Small Cell Lung Cancer | Phase 3 | Status: RECRUITING